SCNLF (Scancell Holdings) YoY EBITDA Growth: 66.67% (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNLF Scancell Holdings PLC SCNLF
22 GF Score
Price $0.14
! 1 Warning Sign
View Full Analysis

What is Scancell Holdings YoY EBITDA Growth?

Scancell Holdings SCNLF 22 YoY EBITDA Growth is 66.67% as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scancell Holdings's YoY EBITDA Growth for the quarter that ended in Oct. 2025 was 66.67%.

Scancell Holdings's EBITDA per Share for the six months ended in Oct. 2025 was $-0.01.

Scancell Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings YoY EBITDA Growth Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.67 80.00 -216.67 52.63 -88.89

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.14 54.55 -500.00 100.00 66.67
SCNLF
22GF Score
Scancell Holdings PLC SCNLF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scancell Holdings's YoY EBITDA Growth for the fiscal year that ended in Apr. 2025 is calculated as:

YoY EBITDA Growth (A: Apr. 2025 )
=(EBITDA per Share (A: Apr. 2025 )-EBITDA per Share (A: Apr. 2024 ))/ | EBITDA per Share (A: Apr. 2024 ) |
=(-0.017--0.009)/ | -0.009 |
=-88.89 %

Scancell Holdings's YoY EBITDA Growth for the quarter that ended in Oct. 2025 is calculated as:

YoY EBITDA Growth (Q: Oct. 2025 )
=(EBITDA per Share (Q: Oct. 2025 )-EBITDA per Share (Q: Oct. 2024 )) / | EBITDA per Share (Q: Oct. 2024 )) |
=(-0.006--0.018)/ | -0.018 |
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 66.67% mean?
Scancell Holdings (SCNLF) has a YoY EBITDA Growth of 66.67% as of Oct. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scancell Holdings and its competitors.
Is Scancell Holdings' YoY EBITDA Growth too high?
Scancell Holdings' current YoY EBITDA Growth is 66.67%. Overall, Scancell Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' YoY EBITDA Growth compare to VRTX and REGN?
Scancell Holdings' YoY EBITDA Growth of 66.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scancell Holdings and its competitors. Scancell Holdings's current YoY EBITDA Growth is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current YoY EBITDA Growth of 66.67%. The current YoY EBITDA Growth is 66.67%. Scancell Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current YoY EBITDA Growth is 66.67% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
22GF Score

Get the complete analysis for SCNLF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price